SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives $12.00 Average PT from Analysts

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has been given a consensus recommendation of “Moderate Buy” by the eleven research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $12.00.

SABS has been the subject of a number of research analyst reports. Citigroup started coverage on shares of SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 price objective for the company. Wall Street Zen raised shares of SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 10th. Rodman & Renshaw restated a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Barclays assumed coverage on shares of SAB Biotherapeutics in a report on Wednesday, June 24th. They set an “overweight” rating and a $13.00 target price for the company. Finally, Weiss Ratings lowered shares of SAB Biotherapeutics from a “sell (d+)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th.

Hedge Funds Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Vivo Capital LLC bought a new position in shares of SAB Biotherapeutics during the third quarter worth approximately $22,954,000. Perceptive Advisors LLC boosted its stake in SAB Biotherapeutics by 700.8% in the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock valued at $24,634,000 after purchasing an additional 5,628,533 shares during the period. RA Capital Management L.P. acquired a new position in SAB Biotherapeutics in the 3rd quarter valued at $8,847,000. Woodline Partners LP acquired a new position in SAB Biotherapeutics in the 3rd quarter valued at $5,730,000. Finally, Spruce Street Capital LP bought a new position in SAB Biotherapeutics during the 4th quarter worth $8,222,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Price Performance

NASDAQ:SABS opened at $3.70 on Tuesday. SAB Biotherapeutics has a 12-month low of $1.85 and a 12-month high of $5.15. The firm has a market capitalization of $336.66 million, a price-to-earnings ratio of -2.85 and a beta of 0.53. The stock’s 50 day moving average price is $3.72 and its two-hundred day moving average price is $3.82. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.01.

SAB Biotherapeutics (NASDAQ:SABS) last issued its earnings results on Thursday, August 6th. The company reported ($0.28) EPS for the quarter, hitting the consensus estimate of ($0.28). On average, analysts anticipate that SAB Biotherapeutics will post -1.17 earnings per share for the current year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.